Repare Therapeutics Inc. (RPTX)
2.650
+0.020 (0.76%)
Inactive · Last trade price
on Jan 27, 2026
Repare Therapeutics Revenue
Repare Therapeutics had revenue of $11.62M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $11.87M, down -82.16% year-over-year. In the year 2024, Repare Therapeutics had annual revenue of $53.48M with 4.58% growth.
Revenue (ttm)
$11.87M
Revenue Growth
-82.16%
P/S Ratio
9.54
Revenue / Employee
$92,016
Employees
129
Market Cap
114.24M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRPTX News
- 7 weeks ago - Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc. - Business Wire
- 2 months ago - Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Business Wire
- 3 months ago - Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. - Business Wire
- 3 months ago - Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewsWire
- 4 months ago - Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value - Benzinga
- 4 months ago - Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc. - Business Wire
- 5 months ago - Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Business Wire
- 7 months ago - Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - Business Wire